Protection, systemic IFNgamma, and antibody responses induced by an ISCOM-based vaccine against a recent equine influenza virus in its natural host.
In the horse, conventional inactivated or subunit vaccines against equine influenza virus (EIV) induce a short-lived antibody-based immunity to infection. Alternative strategies of vaccination have been subsequently developed to mimic the long-term protection induced by natural infection with the virus. One of these approaches is the use of immune-stimulating complex (ISCOM)-based vaccines. ISCOM vaccines induce a strong antibody response and protection against influenza in horses, humans, and a mouse model. Cell-mediated immunity (CMI) has been demonstrated in humans and mice after ISCOM vaccination, but rarely investigated in the horse. The aim of this study was to evaluate EIV-specific immune responses after intra-muscular vaccination with an ISCOM-EIV vaccine (EQUIP F) containing both equine influenza H7N7 (A/eq/Newmarket/77) and H3N8 (A/eq/Borlänge/91 and A/eq/Kentucky/98) strains. The antibody response was measured by single radial haemolysis (SRH) assay using different H3N8 EIV strains. Stimulation of type-1 immunity was evaluated with a recently developed method that measures EIV-specific IFNgamma synthesis by peripheral blood lymphocytes (PBL). The protective efficacy of this ISCOM-based vaccine against challenge infection with a recent equine influenza (H3N8; A/eq/South Africa/4/03) strain was also evaluated. Vaccinated ponies developed elevated levels of EIV-specific SRH antibody and increased percentage of EIV-specific IFNgamma(+) PBL, whereas these responses were only detected after challenge infection in unvaccinated control ponies. Vaccinates showed minimal signs of disease and did not shed virus when challenged shortly after the second immunisation. In conclusion, evidence of type-1 immunity induced by an ISCOM-based vaccine is described for the first time in horses.
Paillot
Romain
R
Animal Health Trust, Centre for Preventive Medicine, Lanwades Park, Newmarket, Suffolk, CB8 7UU, UK. romain.paillot@aht.org.uk
Grimmett
Humphrey
H
Elton
Debra
D
Daly
Janet M
JM
D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis; D018414:CD8-Positive T-Lymphocytes / Q000378:metabolism; D006734:Horse Diseases / Q000097:blood / Q000276:immunology / Q000517:prevention & control*; D006736:Horses; D053123:Influenza A Virus, H3N8 Subtype / Q000276:immunology* / Q000472:pathogenicity; D007252:Influenza Vaccines / Q000627:therapeutic use*; D007371:Interferon-gamma / Q000096:biosynthesis; D009976:Orthomyxoviridae Infections / Q000517:prevention & control / Q000662:veterinary*; D016896:Treatment Outcome; D014611:Vaccination / Q000662:veterinary
D000914:Antibodies, Viral; D007252:Influenza Vaccines; D007371:Interferon-gamma